Open AccessSeroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics
Author(s) -
SKJELDESTAD FINN EGIL,
MEHTA VINAY,
SINGS HEATHER L.,
ØVRENESS TORBJØRN,
TURPIN JENNIFER,
SU LING,
SKJELDESTAD FINN EGIL,
MEHTA VINAY,
SINGS HEATHER L.,
ØVRENESS TORBJØRN,
TURPIN JENNIFER,
SU LING,
BOERCKEL PATRICIA,
ROBERTS CHRISTINE,
BRYAN JANINE,
JANSEN KATHRIN U.,
SKJELDESTAD FINN EGIL,
MEHTA VINAY,
SINGS HEATHER L.,
ØVRENESS TORBJØRN,
TURPIN JENNIFER,
SU LING,
BOERCKEL PATRICIA,
ROBERTS CHRISTINE,
BRYAN JANINE,
JANSEN KATHRIN U.,
ESSER MARK T.,
LIAW KAILI
Publication year - 2008
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1080/00016340701714703
Subject(s) - medicine , seroprevalence , norwegian , hpv infection , cohort , sex organ , epidemiology , gynecology , prospective cohort study , cohort study , obstetrics , serology , immunology , antibody , cervical cancer , cancer , biology , linguistics , philosophy , genetics
Background . Long‐term efficacy evaluations of a quadrivalent HPV type 6/11/16/18 vaccine are ongoing in the Nordic region. As there are limited epidemiological data on HPV infection in Norway, we determined prevalence and identified sociobehavioural correlates of HPV 6/11/16/18 infection in young Norwegian women. Methods . Norwegian ( n = 898) women, aged 16–24 years, were enrolled in a 4‐year prospective study. At enrolment and at 6‐month intervals thereafter, an interview on behavioural data and a gynaecological examination were undertaken. Genital samples were tested for the L1, E6 and E7 genes of HPV‐6/11/16/18, and serum anti‐HPV‐6/11/16/18 levels were measured using a competitive Luminex immunoassay (cLIA). Results . DNA and seroprevalence of HPV 6, 11, 16 or 18 ranged from 0.9 to 16.3% and 2.6 to 16.2%, respectively; and most infected women (∼75%) were infected with only 1 type. Of the HPV DNA positive cases, 54.3, 50.0, 47.3 and 38.5% had detectable HPV 6, 11, 16 or 18 antibodies, respectively. More than 50% of the high‐grade cervical intraepithelial neoplasia (CIN) cases were HPV‐16 or HPV‐18 DNA positive. Lifetime number of partners was the strongest and only predictor of sero‐ and DNA‐positivity across the 4 HPV types. Conclusion . Given the high prevalence of HPV infection among young women with mostly single‐type infection, and the fact that type‐specific HPV screening is not recommended prior to the administration of the quadrivalent HPV vaccine, our data suggest the importance of widespread, rather than targeted, immunisation.